We claim:

1. A combination comprising histamine-3 receptor inverse agonists, acetylcholinesterase inhibitor and NMDA receptor antagonist.

2. The combination as claimed in claim 1, wherein the histamine-3 receptor inverse agonists is selected from the group consisting of:
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide;
or a pharmaceutically acceptable salt thereof.

3. The combination as claimed in claim 1, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

4. The combination as claimed in claim 1, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

5. The combination as claimed in claim 1 or claim 2, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

6. The combination as claimed in any one of the claim 1, 2 or 5, wherein the pharmaceutically acceptable salt of the histamine-3 receptor inverse agonist is,
N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride;
N-[4-(1-Cyclopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate; and
N-[4-(1-Isopropylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide tartrate.

7. The combination as claimed in any one of the claim 1, 2, 5 or 6, wherein the histamine-3 receptor inverse agonist is N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride.

8. The combination as claimed in claim 1 or claim 3, wherein the acetylcholinesterase inhibitor is donepezil or a pharmaceutically acceptable salt thereof.

9. The combination as claimed in any one of the claim 1, 3 or 8, wherein the acetylcholinesterase inhibitor is donepezil hydrochloride.

10. The combination as claimed in claim 1 or claim 4, wherein the NMDA receptor antagonist is memantine hydrochloride.

11. A combination comprising N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride, donepezil hydrochloride and memantine hydrochloride.

12. The combination as claimed in any one of the claim 1 to 11, for use in the treatment of cognitive disorders in a patient.

13. The use as claimed in claim 12, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

14. A method of treatment of cognitive disorders comprising administering to a patient in need thereof, a therapeutically effective amount of the combination as claimed in any one of the claim 1 to 11.

15. The method of treatment as claimed in 14, wherein the cognitive disorder is selected from Alzheimer's disease, schizophrenia, Parkinson's disease, lewy body dementia, vascular dementia, frontotemporal dementia, Down syndrome and Tourette's syndrome.

16. A compound, N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof for use in combination with acetylcholinesterase inhibitor and NMDA receptor antagonist for the treatment of Alzheimer's disease in a patient.

17. The compound for use as claimed in claim 16, as an adjunct treatment in a patient on stable treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist.

18. The compound for use as claimed in the claim 16 or claim 17, wherein the acetylcholinesterase inhibitor is selected from donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

19. The compound for use as claimed in the claim 16 or claim 17, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

20. A method of treating Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor and NMDA receptor antagonist comprising administering to said patient a therapeutically effective amount of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof.

21. The method of treating Alzheimer's disease as claimed in claim 20, wherein the acetylcholinesterase inhibitor is donepezil, rivastigmine and galantamine or a pharmaceutically acceptable salt thereof.

22. The method of treating Alzheimer's disease as claimed in claim 20, wherein the NMDA receptor antagonist is memantine or a pharmaceutically acceptable salt thereof.

23. The method of treating Alzheimer's disease as claimed in claim 20, wherein the patient is administered 0.1 mg to 100 mg of N-[4-(l-Cyclobutylpiperidin-4-

yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof per day.

24. The method of treating Alzheimer's disease as claimed in claim 20, wherein the patient is administered 0.1 mg to 60 mg of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof per day.

25. The method of treating Alzheimer's disease as claimed in claim 20, wherein the patient is administered 0.1 mg to 30 mg of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof per day.

26. The method of treating Alzheimer's disease as claimed in claim 20, wherein the patient is administered 1 mg to 30 mg of donepezil or a pharmaceutically acceptable salt thereof per day.

27. The method of treating Alzheimer's disease as claimed in claim 20, wherein the patient is administered 1 mg to 40 mg of memantine or a pharmaceutically acceptable salt thereof per day.

28. A pharmaceutical composition comprising the combination as claimed in any one of the claim 1 to 11, and pharmaceutically acceptable excipients or combination thereof.

29. The pharmaceutical composition as claimed in claim 28, for use in the treatment of cognitive disorders selected from Alzheimer's disease, schizophrenia, Parkinson's diseases, lewy body dementia, vascular dementia and frontotemporal dementia.

30. The pharmaceutical composition as claimed in claim 28 or claim 29, wherein the N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is present in an amount of 0.1 mg to 100 mg.

31. The pharmaceutical composition as claimed in claim 28 or claim 29, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is present in an amount of 0.1 mg to 60 mg.

32. The pharmaceutical composition as claimed in claim 28 or claim 29, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is present in an amount of 0.1 mg to 30 mg.

33. The pharmaceutical composition as claimed in claim 28 or claim 29, wherein the donepezil or a pharmaceutically acceptable salt thereof is present in an amount of 2 mg to 30 mg.

34. The pharmaceutical composition as claimed in claim 28 or claim 29, wherein the memantine or a pharmaceutically acceptable salt thereof is present in an amount of 1 mg to 40 mg.

35. The method of treating Alzheimer's disease as claimed in claim 20, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is administered to the patient by oral, nasal, local, dermal or parenteral routes.

36. The method of treating Alzheimer's disease as claimed in claim 20, wherein the N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide or a pharmaceutically acceptable salt thereof is administered to the patient one to three times per day, one to three times per week or one to three times per month.